Hanmi Science Co., Ltd. (KRX: 008930)
South Korea
· Delayed Price · Currency is KRW
28,250
+300 (1.07%)
Feb 5, 2025, 9:00 AM KST
Hanmi Science Revenue
Hanmi Science had revenue of 322.47B KRW in the quarter ending September 30, 2024, with 4.24% growth. This brings the company's revenue in the last twelve months to 1.28T, up 6.61% year-over-year. In the year 2023, Hanmi Science had annual revenue of 1.25T with 19.30% growth.
Revenue (ttm)
1,283.65B
Revenue Growth
+6.61%
P/S Ratio
1.48
Revenue / Employee
2.89B
Employees
444
Market Cap
1,892.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,247.91B | 201.85B | 19.30% |
Dec 31, 2022 | 1,046.05B | 95.89B | 10.09% |
Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
Dec 31, 2020 | 857.38B | 40.76B | 4.99% |
Dec 31, 2019 | 816.62B | 108.62B | 15.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,566.25B |
Hanall Biopharma | 134.24B |
Daewoong Pharmaceutical | 1,416.63B |